Trends in Immunotherapy

Case Report

Peristomal pyoderma gangrenosum successfully treated with cyclosporine

Downloads

https://doi.org/10.24294/ti.v6.i2.1474
Urano, S., Abe, J., & Kikuchi, H. (2022). Peristomal pyoderma gangrenosum successfully treated with cyclosporine. Trends in Immunotherapy, 6(2). https://doi.org/10.24294/ti.v6.i2.1474
Volume 6 Issue 2 (2022)

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Shoko Urano
    Department of Dermatology, Jyuzen Memorial Hospital, 1700 Komatsu, Hamamatsu 434-0042, Japan
  • Jinnroh Abe Department of Surgery, Jyuzen Memorial Hospital, Hamamatsu 434-0042, Japan.
  • Hirotoshi Kikuchi Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu 431-3125, Japan

Peristomal pyoderma gangrenosum (PPG) is an uncommon subtype of pyoderma gangrenosum. We describe a 74-year-old woman without inflammatory bowel disease (IBD) who developed PG around the jejunostomy and was successfully treated with cyclosporine. In our case, irritations by a lumbar corset and repeated sutures around the jejunostomy seemed to have caused pathergy reaction. It is noteworthy that 20% of PPG patients do not have IBD and therefore patients presenting PPG without IBD should not be overlooked.

Keywords:

Peristomal Pyoderma Gangrenosum Jejunostomy Pathergy Cyclosporine

References

  1. McGarity WC, Robertson DB, McKeown PP, et al. Pyoderma gangrenosum at the parastomal site in patients with Crohn’s disease. Archives of Surgery 1984; 119(10): 1186–1188. doi: 10.1001/archsurg.1984.01390220064014
  2. Barbosa NS, Tolkachjov SN, el-Azhary RA, et al. Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013. Journal of the American Academy of Dermatology 2016; 75: 931–939. doi: 10.1016/j.jaad.2016.05.044
  3. Afifi L, Sanchez IM, Wallace MM, et al. Diagnosis and management of peristomal pyoderma gangrenosum: A systematic review. Journal of the American Academy of Dermatology 2018; 78: 1195–1204. doi: 10.1016/j.jaad.2017.12.049
  4. Davis C, Wright B. Healing of a pyoderma gangrenosum at the site of a percutaneous endoscopically sited gastrostomy tube without tube removal. Case Reports 2014; 2014: bcr2014204301. doi: 10.1136/bcr-2014-204301
  5. Lockenhofer F, Wollina U, Salva KA, et al. The PARAELSUS score: A novel diagnostic tool for pyoderma gangrenosum. British Journal of Dermatology 2019; 180: 615–620. doi: 10.1111/bjd.16401
  6. Hashizume H, Kageyama R, Umayahara T, et al. A case of pyoderma arthritis, pyoderma gangrenosumu, and acne (PAPA) syndrome successfully treated with combination therapy of corticosteroids, cyclosporine, and colchicine. Trends in Immunotherapy 2018. doi: 10.24294/ti.v2.i2.719
  7. Okuno A, Kanda Y, Nakano H, et al. Therapeutic effects of cyclosporine on Hailey-Hailey disease. Trends in Immunotherapy 2019; 3(1): 58–61. doi: 10.24294/ti.v3.i1.1140